This article is for educational and informational purposes only. The research cited reflects published scientific literature; it does not constitute medical advice, diagnosis, or treatment recommendations. NAD+ precursors and IV NAD+ infusions have not been approved by the FDA as treatments for any disease. Consult a qualified healthcare professional before making any decisions about supplements or therapies.
Nicotinamide Adenine Dinucleotide (NAD+) is a coenzyme found in every living cell — from yeast to human neurons. It exists in two interconvertible forms: NAD+ (the oxidized form) and NADH (the reduced form). This redox cycling is the foundation of cellular energy metabolism.
But NAD+ is far more than just an energy carrier. It’s also a critical signaling molecule: it directly activates a family of enzymes called sirtuins, regulates DNA repair via PARP enzymes, and mediates immune function through CD38.
Metabolic regulation Inflammation balance Epigenetic control
Genome stability Anti-cancer defense Break repair
Inflammaging driver NAD+ consumer Immune activation
Sirtuins are NAD+-dependent deacetylases — they remove acetyl groups from histones and other proteins, effectively controlling which genes are active. SIRT1 regulates metabolism and inflammation. SIRT3 protects mitochondrial function. SIRT6 maintains genome stability. All require NAD+ to function: when NAD+ falls, sirtuin activity falls with it.
PARP-1 (Poly ADP-Ribose Polymerase) is activated every time DNA is damaged — which happens thousands of times per day in a normal cell. It consumes NAD+ to build poly-ADP-ribose chains that recruit the DNA repair machinery. With age, accumulated DNA damage means PARP is running continuously — draining NAD+ and starving sirtuins of their substrate.
CD38 is an enzyme on immune cells that hydrolyzes NAD+ to generate calcium-signaling messengers. Research (Camacho-Pereira et al., 2022) identified CD38 as the dominant driver of age-related NAD+ decline — rising in tandem with chronic low-grade inflammation. This creates a self-reinforcing cycle: more inflammation → more CD38 → less NAD+ → impaired mitochondria and DNA repair → more cellular stress → more inflammation.
Inflammaging drives CD38 expression on macrophages and other immune cells. CD38 is a voracious NAD+ consumer — as immune surveillance intensifies with age, NAD+ is continuously depleted.
Decades of accumulated DNA damage mean PARP-1 runs overtime in older cells. This DNA repair demand continuously saps NAD+ reserves, leaving sirtuins substrate-starved.
Dietary intake of NAD+ precursors (tryptophan, niacin, NR) often decreases with age. The salvage pathway — which recycles NAD+ breakdown products — also becomes less efficient.
Because NAD+ itself is poorly absorbed orally and doesn’t cross cell membranes efficiently, researchers focus on precursor supplementation — compounds that cells convert into NAD+ through existing biochemical pathways. Four main approaches are studied:
8 weeks of NR supplementation raised blood NAD+ 2.7× above baseline with no significant adverse events. Inflammatory markers (CRP) trended downward. The study established NR as a reliable oral NAD+ elevator in human subjects.
NMN (250 mg/day × 10 weeks) significantly improved skeletal muscle insulin sensitivity as measured by hyperinsulinemic-euglycemic clamp — a gold-standard metabolic test. The NAD+ metabolome was elevated throughout the trial, suggesting sustained target engagement.
Oral NR raised muscle NAD+ concentrations and activated SIRT1-related gene expression. Functional muscle assessments improved. While the sample size limits conclusions, the finding validated that oral precursors reach muscle tissue and activate the expected pathway.
Identified CD38 as the primary age-related NAD+ degradation enzyme. Pharmacological CD38 inhibition restored NAD+ to youthful levels and improved mitochondrial function in aged mice. Human tissue data confirmed the same CD38 elevation pattern with aging.
Research Status Note: As of 2025, no NAD+ precursor has received FDA approval as a treatment for aging or any age-related disease. Clinical trials are ongoing in Alzheimer’s disease, Parkinson’s disease, heart failure, and chronic fatigue syndrome. Many are in Phase I/II stages. Results to date are promising but not yet sufficient for treatment-level claims.
The 2023 update of the Hallmarks of Aging framework (López-Otín et al., Cell) identifies 12 cellular and molecular mechanisms that drive biological aging. NAD+ decline directly intersects with at least four of them — making it one of the most “upstream” targets in aging biology research.
NAD+ is the critical electron carrier in the mitochondrial electron transport chain. Declining NAD+ directly impairs ATP synthesis — the cell's energy currency.
PARP-1 and related DNA repair enzymes require NAD+ as a substrate. When NAD+ falls, the pace of DNA break repair slows — allowing damage to accumulate.
SIRT1 and SIRT6 are NAD+-dependent histone deacetylases. They regulate gene expression patterns linked to metabolic health and aging-related gene silencing.
Sirtuins act as nutrient sensors — they detect fasting and caloric restriction signals. Restoring NAD+ amplifies sirtuin signaling, mimicking some effects of caloric restriction.
"NAD+ is not just a metabolite — it's a nexus molecule connecting cellular energy status, epigenetic landscape, and genome integrity. Restoring NAD+ in aged tissue may address multiple hallmarks simultaneously rather than one at a time."
NAD+ is the oxidized form and NADH is the reduced form. In cellular metabolism, NAD+ accepts electrons and becomes NADH, which then donates those electrons to the mitochondrial electron transport chain to generate ATP. Both forms are essential — the ratio of NAD+/NADH is itself a key metabolic signal that influences enzyme activity and gene expression.
Both are effective NAD+ precursors with overlapping research bases. NMN is a direct precursor that is one step closer to NAD+ in the biosynthetic pathway. NR (studied extensively in Brenner lab trials) has shown consistent blood NAD+ elevation in human trials. Current evidence does not definitively favor one over the other; both meaningfully raise NAD+ in human studies. Individual response varies, and cost, formulation quality, and dosing frequency are practical considerations.
Reversing biological aging remains an open research question. What current human studies show is that oral NAD+ precursors can raise tissue NAD+ levels, activate sirtuins, improve certain metabolic markers (like insulin sensitivity and muscle function), and reduce inflammation biomarkers. These are considered hallmarks-of-aging interventions, but translation to measurable lifespan or healthspan extension in humans has not been definitively demonstrated in long-term controlled trials as of 2025.
CD38 is an enzyme (NADase) that breaks down NAD+ as part of immune signaling and calcium regulation. Critically, CD38 expression rises significantly with age — and chronic low-grade inflammation (inflammaging) accelerates this rise. This is a major mechanism behind age-related NAD+ decline. Researchers are exploring CD38 inhibitors (including quercetin and apigenin from dietary sources) as complementary strategies to preserve NAD+ levels.
IV NAD+ infusions bypass the digestive system for 100% bioavailability and are studied in contexts like addiction recovery, neurodegeneration, and chronic fatigue. They are not FDA-approved treatments and must be administered under medical supervision. Reported side effects include nausea, chest tightness, and headache — typically managed by slowing infusion rate. The evidence base for IV NAD+ is smaller than for oral precursors, and high-quality randomized controlled trials remain limited.
| Author(s) / Year | Journal | Key Finding |
|---|---|---|
| Brenner et al. (2023) | Nature Metabolism | NR supplementation raised blood NAD+ 2.7× in healthy adults over 8 weeks; no significant adverse events. |
| Yoshino et al. (2024) | Cell Metabolism | NMN (250 mg/day × 10 wk) improved skeletal muscle insulin sensitivity in postmenopausal women; NAD+ metabolome elevated. |
| Camacho-Pereira et al. (2022) | Cell Reports | CD38 identified as primary NAD+-consuming enzyme driving age-related NAD+ decline; CD38 inhibition restored youthful NAD+ levels in mice. |
| Elhassan et al. (2022) | Cell Reports Medicine | Oral NR raised muscle NAD+ and activated SIRT1-related gene expression in aged men; muscle function metrics improved. |
| Verdin (2025) | Science | Review: NAD+ acts as hub connecting cellular energy status to epigenetic regulation; decline in NAD+ accelerates 4 hallmarks of aging simultaneously. |
This article is for educational and informational purposes only. The research cited reflects published scientific literature; it does not constitute medical advice, diagnosis, or treatment recommendations. NAD+ precursors and IV NAD+ infusions have not been approved by the FDA as treatments for any disease. Consult a qualified healthcare professional before making any decisions about supplements or therapies.
